Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors

Next Previous
X
Search
Trial Profile

Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; Onalespib (Primary) ; Trametinib (Primary)
  • Indications Colon cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Oct 2024 Status changed from active, no longer recruiting to discontinued.
    • 31 May 2020 Results (n=22) determine the safety and efficacy of AT13387, in combination with dabrafenib and trametinib in patients with solid tumors,presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 15 Jan 2019 Planned primary completion date changed from 30 Jun 2018 to 31 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top